Online citations, reference lists, and bibliographies.
← Back to Search

Comparison Of Osteopontin, Megakaryocyte Potentiating Factor, And Mesothelin Proteins As Markers In The Serum Of Patients With Malignant Mesothelioma

J. Creaney, D. Yeoman, Y. Demelker, A. Segal, A. Musk, S. Skates, B. Robinson
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: There is increasing interest in identifying a blood-based marker for the asbestos-related tumor, malignant mesothelioma. Three potential markers for mesothelioma are mesothelin, megakaryocyte potentiating factor (MPF) and osteopontin. The purpose of the current study was to directly compare these biomarkers in the same sample population, determining their sensitivity and specificity in establishing a diagnosis, and to determine if diagnostic accuracy for mesothelioma is improved by combining the data from all three markers. Methods: Serum levels of mesothelin, MPF and osteopontin were determined by commercially available assays in 66 samples from patients with pleural malignant mesothelioma, 20 healthy individuals, 21 patients with asbestos-related lung or pleural disease, 30 patients presenting with benign pleural effusions and 30 patients with other malignancies. Results: Serum levels of the three markers were elevated in mesothelioma patients. At a level of specificity of 95% relative to healthy controls and patients with benign asbestos related disease, the sensitivity for mesothelioma was 34% for MPF, 47% for osteopontin and 73% for mesothelin. Osteopontin and MPF were unable to differentiate patients with mesothelioma from patients with other malignancies or those presenting with transudative pleural effusions. Combining the data from the three biomarkers using a logistic regression model did not improve sensitivity for detecting mesothelioma above that of the mesothelin marker alone. Conclusion: Serum mesothelin remains the most specific marker for the diagnosis of mesothelioma.
This paper references
10.1158/1055-9965.EPI-05-0334
Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker
I. Hellstrom (2006)
10.1016/J.JSS.2004.03.028
The role of Osteopontin in tumor metastasis.
P. Wai (2004)
10.1038/sj.bjc.6601839
Role of osteopontin in tumour progression
S. R. Rittling (2004)
10.1186/1471-2407-4-19
Characterization of human mesothelin transcripts in ovarian and pancreatic cancer
Zhanat E Muminova (2004)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.7326/0003-4819-77-4-507
Pleural effusions: the diagnostic separation of transudates and exudates.
R. Light (1972)
10.1093/AJCP/110.3.397
Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
D. Henderson (1998)
10.1158/1055-9965.EPI-06-0479
Mesothelin Is Shed from Tumor Cells
M. Ho (2006)
10.1158/1078-0432.CCR-03-0801
Mesothelin: a new target for immunotherapy.
R. Hassan (2004)
Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
Ruth Etzioni (2004)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5.
N. Yamaguchi (1994)
10.1200/JCO.2004.03.091
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
S. Skates (2004)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1111/j.1349-7006.2006.00246.x
Novel ELISA system for detection of N‐ERC/mesothelin in the sera of mesothelioma patients
K. Shiomi (2006)
10.1158/1078-0432.CCR-06-0472
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
10.1158/1078-0432.CCR-03-0365
Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer
J. Schorge (2004)
Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiol Biomarkers Prev 2004;13:1640–1645
R Etzioni (2004)
Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma
A. Scherpereel (2006)
10.1016/S0021-9150(03)00298-3
Plasma osteopontin levels are associated with the presence and extent of coronary artery disease.
R. Ohmori (2003)
10.1016/J.RMED.2004.04.018
High plasma concentrations of osteopontin in patients with interstitial pneumonia.
J. Kadota (2005)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
10.1046/j.1365-2303.2000.00247.x
Invited review The cytology of malignant mesothelioma
D. Whitaker (2000)
10.1074/jbc.270.37.21984
Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*)
T. Kojima (1995)
The cytology of malignant mesothelioma.
D. Whitaker (2000)
10.2307/2531595
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
E. R. Delong (1988)



This paper is referenced by
10.1007/978-3-642-10862-4_10
Early stages of mesothelioma, screening and biomarkers.
S. Klebe (2011)
10.1097/MCP.0b013e32832b98eb
Serum and pleural fluid biomarkers for mesothelioma
J. Creaney (2009)
10.1371/journal.pone.0063873
Bacterial Infection Elicits Heat Shock Protein 72 Release from Pleural Mesothelial Cells
Julius F. Varano della Vergiliana (2013)
10.1007/978-2-8178-0021-9_17
Mésothéliome pleural malin
J.-M. Bréchot (2011)
10.1183/09031936.00040911
A breath test for malignant mesothelioma using an electronic nose
Elaine. Chapman (2011)
10.1515/cclm-2012-0314
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
E. Park (2012)
10.1007/978-3-030-16884-1_3
Screening Issues in Exposed Subjects and Early Diagnosis
M. Mencoboni (2019)
10.1371/journal.pone.0025391
LRRN4 and UPK3B Are Markers of Primary Mesothelial Cells
M. Kanamori-Katayama (2011)
An Update on Biomarkers and Treatment
Mandira Ray (2015)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.4155/CLI.11.72
Treatment of malignant pleural mesothelioma: current status and future directions
P. Zucali (2011)
10.1016/j.freeradbiomed.2015.05.002
Malignant mesothelioma as an oxidative stress-induced cancer: An update.
S. H. Chew (2015)
10.2217/fon.11.45
Diagnostic molecular biomarkers for malignant pleural effusions.
K. Sriram (2011)
10.1016/b978-0-12-394384-2.00006-1
Asbestos-Related Disease
J. R. Portal (2012)
10.1586/ers.09.67
Advances in the investigation and treatment of pleural effusions
Eleanor K. Mishra (2010)
10.1016/j.ctrv.2015.05.001
The established and future biomarkers of malignant pleural mesothelioma.
V. Panou (2015)
10.1016/S0300-2896(09)70267-4
Actualización en enfermedad respiratoria y exposición ambiental: una relación invisible
Cristina Martinez Gonzalez (2009)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
10.1002/9781118990957.CH18
Mesothelioma: Screening in the modern age
Joanna Sesti (2018)
10.1097/JTO.0b013e31821e1c08
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
A. Cristaudo (2011)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology
R. Martins (2012)
10.1371/journal.pone.0014640
The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
Xinran Xiang (2011)
10.1007/BF03256303
Biomarkers for Malignant Pleural Mesothelioma
L. Greillier (2012)
highlights several prognostic biomarkers for malignant mesothelioma.
Filip Mundt (2013)
Immunological biomarkers of outcome in thoracic cancers
T. Meniawy (2016)
10.18632/oncotarget.17910
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
Sabrina Lagniau (2017)
10.1016/j.shaw.2020.07.009
Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders
E. Park (2020)
CMAR_A_205723 4997..5012
Diana Ospina (2019)
10.2147/CMAR.S205723
Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos
D. Ospina (2019)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1016/S1877-1203(09)72544-3
Atteinte maligne de la plèvre
Xavier Dhalluin (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar